TumCG Cancer Research Results

TumCG, Tumor cell growth: Click to Expand ⟱
Source:
Type:
Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M).
Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division).
Liver, Liver Cancer: Click to Expand ⟱
Liver Cancer
Scientific Papers found: Click to Expand⟱
5434- AG,    Recent Advances in the Mechanisms and Applications of Astragalus Polysaccharides in Liver Cancer Treatment: An Overview
- Review, Liver, NA
AntiCan↑, Apoptosis↑, TumCP↓, EMT↓, Imm↑, ChemoSen↑, BioAv↓, TumCG↓, IL2↑, IL12↑, TNF-α↑, P-gp↓, MDR1↓, QoL↑, Casp↑, DNAdam↑, Bcl-2↓, BAX↑, MMP↓, Cyt‑c↑, NOTCH1↓, GSK‐3β↓, TumCCA↑, GSH↓, ROS↑, lipid-P↑, c-Iron↑, GPx4↓, ACSL4↑, Ferroptosis↑, Wnt↓, β-catenin/ZEB1↓, cycD1/CCND1↓, Akt↓, PI3K↓, mTOR↓, CXCR4↓, Vim↓, PD-L1↓, eff↑, eff↑, ChemoSen↑, ChemoSen↑, chemoP↑,
5326- ALC,    L-Carnitine Is an Endogenous HDAC Inhibitor Selectively Inhibiting Cancer Cell Growth In Vivo and In Vitro
- vitro+vivo, Liver, HepG2
TumCG↓, P21↑, ac‑H3↑, HDAC↓, *ATP↑, selectivity↑, ac‑H4↑,
5907- CAR,    Anti-proliferative and pro-apoptotic effect of carvacrol on human hepatocellular carcinoma cell line HepG-2
- in-vitro, Liver, HepG2
TumCG↓, Apoptosis↓, Casp3↓, cl‑PARP↑, Bcl-2↓, p‑ERK↓, p‑p38↑, *Bacteria↓, *AntiAg↑, *Inflam↓, *antiOx↑, *AChE↓, AntiTum↑, MMP↓, Cyt‑c↑, Bax:Bcl2↑, Casp↑, DNAdam↑, selectivity↑,
465- CUR,    Curcumin inhibits the growth of liver cancer by impairing myeloid-derived suppressor cells in murine tumor tissues
- vitro+vivo, Liver, HepG2 - vitro+vivo, Liver, HUH7 - vitro+vivo, Liver, MHCC-97H
TumCG↓, MDSCs↓, TLR4↓, NF-kB↓, IL6↓, IL1↓, PGE2↓, COX2↓, GM-CSF↓, angioG↓, VEGF↓, CD31↓, GM-CSF↓, α-SMA↓, p‑IKKα↓, MyD88↓,
2859- FIS,    The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways
- in-vitro, Liver, HepG2 - NA, Colon, Caco-2
TumCG↓, other↝, Casp3↑, Casp7↑, PGE2↓, GSTs↓, Wnt↓, EGFR↓, NF-kB↓, COX2↓, P53↑, P21↑, P450↓,
1918- JG,    ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro
- in-vitro, Liver, HepG2 - in-vivo, NA, NA
TumCG↓, TumCP↓, Apoptosis↑, TumAuto↑, AMPK↑, mTOR↑, P53↑, H2O2↑, ROS↑, toxicity↝, p62↓, DR5↑, Casp8↑, PARP↑, cl‑Casp3↑,
5117- JG,    https://pubmed.ncbi.nlm.nih.gov/31283929/
- vitro+vivo, Liver, NA
TumCG↓, TumCP↓, Apoptosis↑, TumAuto↑, AMPK↑, mTOR↑, P53↑, H2O2↑, ROS↑,
2261- MF,    Tumor-specific inhibition with magnetic field
- in-vitro, Nor, GP-293 - in-vitro, Liver, HepG2 - in-vitro, Lung, A549
ROS↑, Ca+2↓, Apoptosis↑, *selectivity↑, TumCG↓, *i-Ca+2↓, i-Ca+2↑,
507- MF,    Effects of extremely low frequency electromagnetic fields on the tumor cell inhibition and the possible mechanism
- in-vitro, Liver, HepG2 - in-vitro, Lung, A549 - in-vitro, Nor, GP-293
MMP↓, TumCG↓, ROS↑, *Ca+2↓, Ca+2↑, selectivity↑, i-pH↑,
221- MFrot,  MF,    Low Frequency Magnetic Fields Enhance Antitumor Immune Response against Mouse H22 Hepatocellular Carcinoma
- in-vivo, Liver, NA
OS↑, TumCG↓, IL6↓, GM-CSF↓, CXCc↓, Macrophages↑, DCells↑, CD4+↑, CD8+↑, IL12↑,
2077- PB,    Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells
- in-vitro, Liver, HUH7
miR-22↑, SIRT1↓, ROS↑, Cyt‑c↑, Casp3↑, eff↓, TumCG↓, TumCP↓, HDAC↓, SIRT1↓, CD44↓, proMMP2↓, MMP↓, SOD↓,
5155- PTL,    Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases
- in-vitro, Liver, HepG2 - in-vitro, Nor, MEF - in-vitro, Cerv, HeLa - in-vitro, BC, MDA-MB-453
JAK↓, ROS↑, TumCMig↓, TumCG↓, STAT3↓,
43- QC,    Investigation of the anti-cancer effect of quercetin on HepG2 cells in vivo
- in-vivo, Liver, HepG3
cycD1/CCND1↓, TumCG↓, TumCP↓,
4486- Se,  Chit,    Selenium-Modified Chitosan Induces HepG2 Cell Apoptosis and Differential Protein Analysis
- in-vitro, Liver, HepG2
Apoptosis↑, TumCCA↑, MMP↓, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Risk↓, *BioAv↑, *toxicity↑, TumCG↓, AntiTum↑, ROS↑, Cyt‑c↑, Fas↑, FasL↑, FADD↑,
2359- SK,    Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
- in-vivo, Liver, NA
TumCG↓, PKM2↓, EMT↓, TGF-β↓, Glycolysis↓, lactateProd↓, ATP↓,

Showing Research Papers: 1 to 15 of 15

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 15

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 1,   GSTs↓, 1,   H2O2↑, 2,   c-Iron↑, 1,   lipid-P↑, 1,   ROS↑, 8,   SOD↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 5,  

Core Metabolism/Glycolysis ⓘ

ACSL4↑, 1,   AMPK↑, 2,   Glycolysis↓, 1,   lactateProd↓, 1,   PKM2↓, 1,   SIRT1↓, 2,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↓, 1,   Apoptosis↑, 5,   BAX↑, 2,   Bax:Bcl2↑, 1,   Bcl-2↓, 3,   Casp↑, 2,   Casp3↓, 1,   Casp3↑, 2,   cl‑Casp3↑, 2,   Casp7↑, 1,   Casp8↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 4,   DR5↑, 1,   FADD↑, 1,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 1,   p‑p38↑, 1,  

Transcription & Epigenetics ⓘ

ac‑H3↑, 1,   ac‑H4↑, 1,   other↝, 1,  

Autophagy & Lysosomes ⓘ

p62↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   P53↑, 3,   PARP↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 2,   P21↑, 2,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   EMT↓, 2,   p‑ERK↓, 1,   GSK‐3β↓, 1,   HDAC↓, 2,   mTOR↓, 1,   mTOR↑, 2,   NOTCH1↓, 1,   PI3K↓, 1,   STAT3↓, 1,   TumCG↓, 15,   Wnt↓, 2,  

Migration ⓘ

Ca+2↓, 1,   Ca+2↑, 1,   i-Ca+2↑, 1,   CD31↓, 1,   miR-22↑, 1,   proMMP2↓, 1,   TGF-β↓, 1,   TumCMig↓, 1,   TumCP↓, 5,   Vim↓, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   COX2↓, 2,   CXCc↓, 1,   CXCR4↓, 1,   DCells↑, 1,   GM-CSF↓, 3,   p‑IKKα↓, 1,   IL1↓, 1,   IL12↑, 2,   IL2↑, 1,   IL6↓, 2,   Imm↑, 1,   JAK↓, 1,   Macrophages↑, 1,   MDSCs↓, 1,   MyD88↓, 1,   NF-kB↓, 2,   PD-L1↓, 1,   PGE2↓, 2,   TLR4↓, 1,   TNF-α↑, 1,  

Cellular Microenvironment ⓘ

i-pH↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   ChemoSen↑, 3,   eff↓, 1,   eff↑, 2,   MDR1↓, 1,   P450↓, 1,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   IL6↓, 2,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 2,   chemoP↑, 1,   OS↑, 1,   QoL↑, 1,   Risk↓, 1,   toxicity↝, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 117

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,  

Migration ⓘ

AntiAg↑, 1,   Ca+2↓, 1,   i-Ca+2↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

toxicity↑, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 11

Scientific Paper Hit Count for: TumCG, Tumor cell growth
3 Magnetic Fields
2 Juglone
1 Astragalus
1 Acetyl-l-carnitine
1 Carvacrol
1 Curcumin
1 Fisetin
1 Magnetic Field Rotating
1 Phenylbutyrate
1 Parthenolide
1 Quercetin
1 Selenium
1 chitosan
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:14  Cells:%  prod#:%  Target#:323  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page